JPWO2020097394A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020097394A5 JPWO2020097394A5 JP2021525169A JP2021525169A JPWO2020097394A5 JP WO2020097394 A5 JPWO2020097394 A5 JP WO2020097394A5 JP 2021525169 A JP2021525169 A JP 2021525169A JP 2021525169 A JP2021525169 A JP 2021525169A JP WO2020097394 A5 JPWO2020097394 A5 JP WO2020097394A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- delivery construct
- amino acid
- acid sequence
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 239000000969 carrier Substances 0.000 claims description 32
- 102000034388 naturally occurring fusion proteins Human genes 0.000 claims description 29
- 108091006032 naturally occurring fusion proteins Proteins 0.000 claims description 29
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- 200000000018 inflammatory disease Diseases 0.000 claims description 9
- 238000005571 anion exchange chromatography Methods 0.000 claims description 8
- 230000031998 transcytosis Effects 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- 229940099500 Cystamine Drugs 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010011401 Crohn's disease Diseases 0.000 claims description 5
- 201000006704 ulcerative colitis Diseases 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 238000005277 cation exchange chromatography Methods 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- 206010018651 Graft versus host disease Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 210000003000 Inclusion Bodies Anatomy 0.000 claims description 3
- 208000002389 Pouchitis Diseases 0.000 claims description 3
- 206010036774 Proctitis Diseases 0.000 claims description 3
- 230000003196 chaotropic Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960002989 Glutamic Acid Drugs 0.000 claims description 2
- 208000006454 Hepatitis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 210000001503 Joints Anatomy 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 201000009846 fatty liver disease Diseases 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000003381 solubilizing Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 229960004198 Guanidine Drugs 0.000 claims 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical group [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862756889P | 2018-11-07 | 2018-11-07 | |
US62/756,889 | 2018-11-07 | ||
USPCT/US2019/021474 | 2019-03-08 | ||
PCT/US2019/021474 WO2019173787A1 (en) | 2018-03-08 | 2019-03-08 | Toxin-derived delivery constructs for oral delivery |
US201962888238P | 2019-08-16 | 2019-08-16 | |
US201962888133P | 2019-08-16 | 2019-08-16 | |
US62/888,133 | 2019-08-16 | ||
US62/888,238 | 2019-08-16 | ||
USPCT/US2019/050708 | 2019-09-11 | ||
PCT/US2019/050708 WO2020096695A1 (en) | 2018-11-07 | 2019-09-11 | Cholix-derived carriers for oral delivery of heterologous payload |
PCT/US2019/060356 WO2020097394A1 (en) | 2018-11-07 | 2019-11-07 | Delivery constructs for transcytosis and related methods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022506990A JP2022506990A (ja) | 2022-01-17 |
JPWO2020097394A5 true JPWO2020097394A5 (ko) | 2022-11-01 |
Family
ID=70612266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021525169A Pending JP2022506990A (ja) | 2018-11-07 | 2019-11-07 | トランスサイトーシスのための送達構築物および関連する方法 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11027020B2 (ko) |
EP (2) | EP4083058A3 (ko) |
JP (1) | JP2022506990A (ko) |
KR (1) | KR20210110294A (ko) |
CN (1) | CN113423722A (ko) |
AU (1) | AU2019377117A1 (ko) |
BR (1) | BR112021009003A2 (ko) |
CA (1) | CA3119060A1 (ko) |
CL (1) | CL2021001209A1 (ko) |
CO (1) | CO2021007402A2 (ko) |
DK (1) | DK3650037T3 (ko) |
EA (1) | EA202191280A1 (ko) |
ES (1) | ES2911075T3 (ko) |
IL (1) | IL282987B2 (ko) |
MX (1) | MX2021005346A (ko) |
PL (1) | PL3650037T3 (ko) |
PT (1) | PT3650037T (ko) |
SG (1) | SG11202104721RA (ko) |
TW (1) | TW202031678A (ko) |
WO (1) | WO2020097394A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
PL3762009T3 (pl) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego |
PL3650037T3 (pl) | 2018-11-07 | 2022-06-06 | Applied Molecular Transport Inc. | Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby |
JP2022512976A (ja) | 2018-11-07 | 2022-02-07 | アプライド モレキュラー トランスポート インコーポレイテッド | 異種ペイロードの経口送達のためのコリックス由来担体 |
WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
JP2023530095A (ja) * | 2020-06-09 | 2023-07-13 | アイコサバックス, インコーポレイテッド | ウイルス様粒子を作製する方法 |
CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
DE3680924D1 (de) | 1985-01-14 | 1991-09-26 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
US6051405A (en) | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
DE60136281D1 (de) * | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
ES2332261T3 (es) | 2000-11-27 | 2010-02-01 | Powderject Vaccines, Inc. | Adyuvantes de acidos nucleicos. |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
US20050074462A1 (en) | 2001-05-23 | 2005-04-07 | Duotol Ab | Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof |
DE602004030341D1 (de) * | 2003-06-23 | 2011-01-13 | Genetics Inst Llc | Antikörper gegen interleukin-22 und verwendungen dafür |
EP1522585A1 (en) | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
WO2006135428A2 (en) | 2004-10-04 | 2006-12-21 | Trinity Biosystems, Inc. | Methods and compositions for inducing an immune response against multiple antigens |
AU2005296064A1 (en) | 2004-10-04 | 2006-04-27 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
US20090148401A1 (en) | 2005-12-05 | 2009-06-11 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
WO2008011157A2 (en) * | 2006-07-20 | 2008-01-24 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
US20100143481A1 (en) | 2006-11-08 | 2010-06-10 | Dinesh Shenoy | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
EP2178559B1 (en) * | 2007-07-20 | 2015-06-24 | The General Hospital Corporation | Recombinant vibrio cholerae exotoxins |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
US20110250199A1 (en) | 2008-06-04 | 2011-10-13 | The Government of the United States of America as represented by the Secretary of the Department.... | Immunotoxins and uses thereof |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
CN102482321B (zh) * | 2009-06-22 | 2015-06-17 | 安姆根有限公司 | 使用化学控制的氧化还原态重折叠蛋白质 |
US20120258104A1 (en) | 2009-07-22 | 2012-10-11 | Cenix Bioscience Gmbh | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
CN105541978B (zh) | 2010-09-15 | 2019-12-13 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
US20140065172A1 (en) | 2011-01-26 | 2014-03-06 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
AU2012275112B2 (en) | 2011-06-29 | 2017-07-06 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
SG11201507429TA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
CN112386680A (zh) | 2013-11-07 | 2021-02-23 | 纪念斯隆–凯特林癌病中心 | 在胃肠道移植物抗宿主病的治疗中使用il-22的方法 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
KR102598038B1 (ko) | 2014-05-07 | 2023-11-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자 |
CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
CA2969574A1 (en) * | 2014-12-23 | 2016-06-30 | Armo Biosciences, Inc. | Methods of improving yield in recombinant protein production |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
JP7084881B2 (ja) | 2016-06-22 | 2022-06-15 | アルカームス インコーポレーテッド | Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
US11523772B2 (en) | 2016-12-14 | 2022-12-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
CA3093386A1 (en) * | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
PL3650037T3 (pl) | 2018-11-07 | 2022-06-06 | Applied Molecular Transport Inc. | Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby |
JP2022512976A (ja) | 2018-11-07 | 2022-02-07 | アプライド モレキュラー トランスポート インコーポレイテッド | 異種ペイロードの経口送達のためのコリックス由来担体 |
US20200140511A1 (en) | 2018-11-07 | 2020-05-07 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
-
2019
- 2019-11-07 PL PL19207825T patent/PL3650037T3/pl unknown
- 2019-11-07 KR KR1020217017210A patent/KR20210110294A/ko unknown
- 2019-11-07 BR BR112021009003-7A patent/BR112021009003A2/pt unknown
- 2019-11-07 AU AU2019377117A patent/AU2019377117A1/en active Pending
- 2019-11-07 WO PCT/US2019/060356 patent/WO2020097394A1/en active Application Filing
- 2019-11-07 ES ES19207825T patent/ES2911075T3/es active Active
- 2019-11-07 DK DK19207825.1T patent/DK3650037T3/da active
- 2019-11-07 MX MX2021005346A patent/MX2021005346A/es unknown
- 2019-11-07 EP EP22159495.5A patent/EP4083058A3/en not_active Withdrawn
- 2019-11-07 JP JP2021525169A patent/JP2022506990A/ja active Pending
- 2019-11-07 SG SG11202104721RA patent/SG11202104721RA/en unknown
- 2019-11-07 CN CN201980088287.9A patent/CN113423722A/zh active Pending
- 2019-11-07 EA EA202191280A patent/EA202191280A1/ru unknown
- 2019-11-07 TW TW108140533A patent/TW202031678A/zh unknown
- 2019-11-07 CA CA3119060A patent/CA3119060A1/en active Pending
- 2019-11-07 EP EP19207825.1A patent/EP3650037B1/en active Active
- 2019-11-07 PT PT192078251T patent/PT3650037T/pt unknown
-
2020
- 2020-06-15 US US16/902,256 patent/US11027020B2/en active Active
-
2021
- 2021-04-20 US US17/235,567 patent/US20210338828A1/en not_active Abandoned
- 2021-05-06 IL IL282987A patent/IL282987B2/en unknown
- 2021-05-07 CL CL2021001209A patent/CL2021001209A1/es unknown
- 2021-06-07 CO CONC2021/0007402A patent/CO2021007402A2/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4585037B2 (ja) | アシル化glp−1化合物 | |
JP5755398B2 (ja) | 伸長されたglp−1化合物 | |
Gagelmann et al. | Urodilatin (CDD/ANP‐95‐126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (α‐hANP/CDD‐99‐126) | |
JP2523843B2 (ja) | 卵胞刺激ホルモン | |
US11027020B2 (en) | Delivery constructs for transcytosis and related methods | |
US20200140511A1 (en) | Delivery constructs for transcytosis and related methods | |
CA2634495A1 (en) | Process for the production of preformed conjugates of albumin and a therapeutic agent | |
JP2010538042A (ja) | グルカゴン様ペプチド−1誘導体及びそれらの医薬用途 | |
JP2010538049A (ja) | 切断型glp−1誘導体及びその治療的使用 | |
JP2010538048A (ja) | A−b−c−d−で誘導体化されたペプチドとその治療用途 | |
Zhao et al. | Recombinant production of medium-to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag | |
HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
JPWO2020097394A5 (ko) | ||
Haladová et al. | The combination of hydrogen/deuterium exchange or chemical cross-linking techniques with mass spectrometry: Mapping of human 14-3-3ζ homodimer interface | |
CN105777862A (zh) | 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子 | |
Yu et al. | Expressed protein ligation for the preparation of fusion proteins with cell penetrating peptides for endotoxin removal and intracellular delivery | |
JP2019518713A5 (ko) | ||
Ueda et al. | Ni (II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts | |
US20190276495A1 (en) | Ebola virus vaccine | |
JP2020529845A5 (ko) | ||
Abolliel et al. | Synthesis, cloning and expression of a novel pre-miniproinsulin analogue gene in Escherichia coli | |
Fazen et al. | Expression and purification of human PYY (3–36) in Escherichia coli using a His-tagged small ubiquitin-like modifier fusion | |
Arakawa | Isoform separation by a mixed-mode resin, TOYOPEARL MX-Trp-650M | |
EA043603B1 (ru) | Конструкции для доставки для трансцитоза и связанные способы | |
CN100564393C (zh) | 含有外消旋化的氨基酸的多肽之分离 |